The Trial That Answered a Different Patient's Question
A long-term transplant recipient's fourth skin cancer puts a well-known immunosuppression switch on the table — except the trial behind that switch found its benefit disappear in patients with a history exactly like his.
Walter H., a 67-year-old retired postal carrier, received a deceased-donor kidney nineteen years ago after hypertensive nephrosclerosis, and has outlived most of his own transplant cohort from that era — a fact his transplant team notes with real satisfaction even as it has come with a predictable cost accumulating alongside it. He is fair-skinned, spent thirty years walking an outdoor mail route before retiring five years ago, and has no other major medical history beyond the transplant itself: no diabetes, no cardiac disease, graft function that has been remarkably stable for a nineteen-year course. What has not been stable is his skin: he has developed cutaneous squamous cell carcinomas with increasing frequency over the past four years, one excised at each of four separate visits, most recently a lesion on his forearm invasive enough on pathology that dermatology flagged it directly to the transplant service rather than simply excising it and scheduling routine follow-up the way the first three were handled.
Sirolimus conversion is the standard next conversation in this situation, and the evidence behind it is genuinely strong at the population level — Dantal and colleagues' 2018 five-year extension of the TUMORAPA trial, following kidney transplant recipients with at least one prior invasive squamous cell carcinoma, found new squamous cell carcinoma in 22% of patients converted to sirolimus against 59% who stayed on calcineurin-inhibitor therapy, a real and durable difference sustained across the full follow-up period. What the same trial's own subgroup analysis found, and what makes Walter's case meaningfully less straightforward than the headline number alone suggests, is that this benefit held clearly for patients entering the trial with a single prior tumor and was lost — not reversed, but no longer statistically distinguishable from chance in a smaller subgroup — in patients who, like Walter, already had multiple tumors before conversion was ever considered. He is, by the trial's own internal accounting rather than by anyone's outside reading of it, not quite the patient the headline result was built on.
The fourth excision, and a conversion that may not apply to him
Convert him to sirolimus. Dantal and colleagues' five-year extension of TUMORAPA is the longest follow-up we have on this question, and a drop from 59% to 22% new squamous cell carcinoma is not a marginal signal — it's one of the more robust findings in transplant dermatology.
Four tumors in four years, with the most recent one invasive enough that I flagged it myself rather than just excising it, is not a picture where I'm comfortable waiting for a cleaner subgroup match before acting on the best population-level evidence we have.
I take the headline number seriously, but the same trial that produced it also found the benefit wasn't statistically significant in patients who already had multiple tumors before conversion — which is Walter, specifically, not a nearby approximation of him.
'A robust population-level finding' and 'a finding that held up in his specific subgroup' are two different claims, and the second one is the one that actually applies to whether he benefits. Converting him carries a documented discontinuation rate of roughly a third of patients (22 of 64) over the full five years, driven by real side effects — mouth ulcers, edema, lipid changes — and I don't think it's unreasonable to ask for more than a headline number before accepting that trade in a subgroup the trial itself flagged as uncertain.
Both of you are debating the benefit side of this trade. I'd point at the cost side: Fázio and colleagues' more recent prospective study using a stepwise conversion without an attack dose found meaningfully better tolerability than the original TUMORAPA protocol, in a population selected specifically for high-risk, poor-prognosis squamous cell carcinoma.
If we're genuinely uncertain whether the benefit applies to him given his tumor history, a gentler conversion protocol lowers the cost of finding out without committing him to the full discontinuation risk the original trial protocol carried. And reducing his overall immunosuppression outright, rather than converting drug classes, isn't a safer alternative — it trades a skin cancer risk we're at least trying to address for a rejection risk with no compensating benefit at all.
Agreed: stepwise conversion to sirolimus begins, tacrolimus tapered rather than stopped outright during the transition, with dermatologic follow-up at three-month intervals rather than the standard six. The pharmacist's proposal to lower the cost of finding out, rather than resolving the efficacy debate outright, is what let the dermatologist and nephrologist agree on a plan without either fully conceding the point.
Explicitly unresolved, and stated as such to Walter directly: whether this conversion will actually reduce his risk of a fifth tumor is genuinely uncertain given his specific history, since the trial's own data couldn't answer that question with confidence in patients who already had multiple tumors like his. Nobody at the table pretended otherwise.